Our Mission

The hematology/oncology team at the University of Michigan is a national leader in clinical practice, research, and education. With specialists in hematology, bone marrow transplant, pediatric hematology/oncology, medical oncology, neuro-oncology, gynecologic oncology and obstetrics & gynecology, the hematology/oncology team offers a diverse array of clinical services to patients. The vision of the University of Michigan hematology/oncology team is to provide the highest level clinical care in the country, drive practice-changing research forward, and to engage students and residents in a challenging and immersive learning environment.

Recent Publications

• A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage (May 2019)

The creation of a multidisciplinary asparaginase allergy committee (MAARC) and therapeutic drug monitoring significantly reduced the Erwinia switch rate from 21% to 7%, resulting in multi-million dollar cost-savings and significant benefit for patients.

• Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy (April 2019)

Highlighted as an Editor's Choice article in Open Forum Infectious , the leukemia team at UM has demonstrated that the risk of proven/probable invasive mold infection (IMI) is not increased with micafungin prophylaxis; older age and relapsed/refractory AML patients are at highest risk of breakthrough IMI.

• PET-guided, BEACOPPesc therapy in advanced Hodgkin lymphoma (April 2019)

A provocative letter to the editor in response to the AHL2011 trial. "Until a randomized trial comparing PET-adapted upfront ABVD versus PET-adapted upfront BEACOPPesc shows an overall survival benefit, we should first do no harm and opt for less intensive upfront regimens."

• The leukemia strikes back: a review of pathogenesis and treatment of secondary AML (Mar 2019)

The leukemia group at the University of Michigan has crafted a comprehensive review of secondary AML, encompassing outcomes, pathophysiology, and controversial data behind recent advances in treatment.

Learn more about the research endeavors of the University of Michigan Hematology/Oncology team

Upcoming Events & Other News